Compare EPAM Systems Inc (EPAM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Zoetis Inc — how do they compare? EPAM Systems Inc trades at $87.42 (market cap $4.49B), while Zoetis Inc trades at $77 (market cap $31.25B). The key difference: Zoetis Inc is far larger — about 7× EPAM Systems Inc's market cap, and Zoetis Inc pays a 2.84% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | ZTS | |
|---|---|---|
Market Cap | $4.49B | $31.25B |
Sector | Technology | Health |
52-Week High | $221.40 | $156.76 |
52-Week Low | $76.04 | $71.91 |
Enterprise Value | $3.74B | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $88.59, up 4.84% today, with a bearish technical signal but strong fundamentals including a P/E of 12.35 and P/S of 0.86. Recent earnings beats and a consensus analyst price target of $128.55 suggest undervaluation, while cash flow trends show operational strength despite a net decline in 2026 projections. The stock faces headwinds from AI sector volatility but benefits from strategic partnerships and AI-native revenue growth.
The outlook for EPAM is cautiously optimistic, with significant upside potential based on analyst targets, though risks include competitive pressures and macroeconomic uncertainty. Investment opportunity lies in its valuation discount and digital engineering expertise, but investors should monitor execution on AI initiatives and sector sentiment shifts for near-term direction.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
